Neurocrine Biosciences President and CEO, Kevin Gorman, said there are few treatments for endometriosis.

Neurocrine Biosciences President and CEO, Kevin Gorman, said there are few treatments for endometriosis.

NEUROCRINE BIOSCIENCES INC.

CEO: Kevin Gorman.

Revenue: $77.4 million in 2011; $33.5 million in 2010.

Net income or loss: Net income of $37.6 million in 2011; net loss of $8 million in 2010.

No. of local employees: About 80 full time.

Headquarters: San Diego.

Year founded: 1992.

Stock symbol and exchange: NBIX on Nasdaq.

Company description: Discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders.

Key factors for success: Concentration on building a product portfolio focused on neurological and endocrine-related diseases and disorders; identifying novel drugs to address unmet market opportunities; establishing corporate collaborations with global pharmaceutical companies to assist in the development of products and mitigate financial risk while retaining commercial upside; acquiring rights to complementary drug candidates and technologies.

Diversification is a key ingredient in Neurocrine Biosciences Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • NEW: San Diego 500 — influential business leaders you need to know
Yours for only $129